API China, a leading exhibition for China's entire pharmaceutical manufacturing sector, enjoyed a robust turnout during the three-day show in Shenzhen from 13-15 November 2007.

API China, a leading exhibition for China's entire pharmaceutical manufacturing sector, enjoyed a robust turnout during the three-day show in Shenzhen from 13--15 November 2007. On the first day, over 18,000 trade professionals packed the halls that spanned 45,000 [m.sup.2]--about the area of seven football fields. In total, more than 30,000 dealers, buyers and sellers of ingredients, intermediates, fine and specialty chemicals, excipients, raw materials, packaging materials, processing and packaging machinery attended this biannual event to trade, source and network with their domestic and international counterparts.

To accentuate API China's importance as a key platform for discussions in the industry, 14 conferences and 18 seminars were held to offer industry insights and share peer-to-peer know-how. API China's supporting partner, the China Pharmaceutical Industry Association (CPIA), held an official meeting to update its association members on policy adjustments and important developments in the industry. CPIA helmed two key seminars that addressed topics such as the Intellectual Property Protection of New Drug in China, Impacts of Government Tax Policy on the Pharmaceutical Industry in China, and Insuring Market Access to the US and EU: Meeting Standards and Managing Product Liability Risks.

"As a leading organizer of pharmaceutical and healthcare events such as API China and INTERPHEX China, we work closelywith government and industry associations to promote industry best practices, commented Kun Ping Hu, Vice President of Reed Sinopharm Exhibitions (RSE). "We believe in doing our part to uphold the standards of excellence in the pharmaceutical industry by running education programs for domestic exhibitors who are looking to internationalize. We also have an IP booth at the show to facilitate original proprietorship of ideas."